AU2018254556B2 - Compositions and methods for treating retinopathy - Google Patents

Compositions and methods for treating retinopathy Download PDF

Info

Publication number
AU2018254556B2
AU2018254556B2 AU2018254556A AU2018254556A AU2018254556B2 AU 2018254556 B2 AU2018254556 B2 AU 2018254556B2 AU 2018254556 A AU2018254556 A AU 2018254556A AU 2018254556 A AU2018254556 A AU 2018254556A AU 2018254556 B2 AU2018254556 B2 AU 2018254556B2
Authority
AU
Australia
Prior art keywords
tyrosine
methyl
subject
hydroxylase inhibitor
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018254556A
Other languages
English (en)
Other versions
AU2018254556A1 (en
Inventor
Steven Hoffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2018254556A1 publication Critical patent/AU2018254556A1/en
Application granted granted Critical
Publication of AU2018254556B2 publication Critical patent/AU2018254556B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AU2018254556A 2017-04-21 2018-04-20 Compositions and methods for treating retinopathy Active AU2018254556B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488161P 2017-04-21 2017-04-21
US62/488,161 2017-04-21
PCT/US2018/028552 WO2018195411A1 (en) 2017-04-21 2018-04-20 Compositions and methods for treating retinopathy

Publications (2)

Publication Number Publication Date
AU2018254556A1 AU2018254556A1 (en) 2019-11-14
AU2018254556B2 true AU2018254556B2 (en) 2024-05-02

Family

ID=62117055

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018254556A Active AU2018254556B2 (en) 2017-04-21 2018-04-20 Compositions and methods for treating retinopathy

Country Status (11)

Country Link
US (2) US11351136B2 (cg-RX-API-DMAC7.html)
EP (1) EP3612225A1 (cg-RX-API-DMAC7.html)
JP (1) JP7171611B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190138683A (cg-RX-API-DMAC7.html)
CN (1) CN110769855A (cg-RX-API-DMAC7.html)
AU (1) AU2018254556B2 (cg-RX-API-DMAC7.html)
CA (1) CA3060417A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992515A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019012476A (cg-RX-API-DMAC7.html)
PH (1) PH12019502380A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018195411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128460A1 (en) * 2012-03-29 2014-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2015061288A1 (en) * 2013-10-22 2015-04-30 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451422A1 (en) * 1990-04-13 1991-10-16 Merrell Dow Pharmaceuticals Inc. Pharmaceutically active fluoromethyltyrosine compounds
MXPA02002559A (es) * 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
JP4758581B2 (ja) 1999-11-30 2011-08-31 アルコン,インコーポレイテッド 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
EP2114386B9 (en) 2007-01-29 2013-09-18 Vlife Sciences Technologies Pvt Ltd. Pharmaceutical composition for treatment of diabetic complications
AU2008347005B2 (en) 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods
JP6836991B2 (ja) 2014-12-23 2021-03-03 スティーブン・ホフマン 経皮製剤
US9687528B2 (en) 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128460A1 (en) * 2012-03-29 2014-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2015061288A1 (en) * 2013-10-22 2015-04-30 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
US20180303783A1 (en) 2018-10-25
US11351136B2 (en) 2022-06-07
AU2018254556A1 (en) 2019-11-14
KR20190138683A (ko) 2019-12-13
JP7171611B2 (ja) 2022-11-15
MX2019012476A (es) 2020-02-12
CN110769855A (zh) 2020-02-07
US20220288003A1 (en) 2022-09-15
PH12019502380A1 (en) 2020-09-14
EP3612225A1 (en) 2020-02-26
US12364676B2 (en) 2025-07-22
CA3060417A1 (en) 2018-10-25
JP2020517663A (ja) 2020-06-18
EA201992515A1 (ru) 2020-04-09
WO2018195411A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
AU2020203101B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
US10857118B2 (en) Compositions and methods for treating intestinal hyperpermeability
US12364676B2 (en) Compositions and methods for treating retinopathy
CN107835695A (zh) 用于治疗自闭症的组合物和方法
US20170151242A1 (en) Composition and method for treating or preventing skeletal muscle fibrosis
EA046053B1 (ru) Композиции и способы для лечения ретинопатии
AU2013270622B2 (en) Composition and method for treating or preventing skeletal muscle fibrosis
AU2018202423A1 (en) Composition and method for treating or preventing skeletal muscle fibrosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)